StreetAlpha.app
Home › Stocks › OCGN

Ocugen, Inc. (OCGN)

Healthcare
$0.76
▼ −2.11%
LAST CLOSE · NOV 17

Ocugen develops gene therapies aimed at treating inherited retinal diseases and other conditions that cause vision loss. It last closed at $0.76 on Nov 17, down 2.11% on the day.

AI Auto Pilots
Is OCGN in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$4.8M
−11.0% vs a year ago
Net income
−$65.4M
−1367.3% margin
Free cash flow
−$63.9M
−1336.9% margin
Operating margin
−1444.1%
−$69.0M operating income
Valuation
Market cap
$256.8M
339.3M shares
P/E
–
Price to sales
53.7
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$24.6M
At Sep 30
Debt
$1.8M
At Sep 30
Shareholder equity
−$17.7M
Shares outstanding
339.3M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $0$0FY2021FY2022: $2.5M$2.5MFY2022FY2023: $6.0M$6.0MFY2023FY2024: $4.1M$4.1MFY2024FY2025: $4.4M$4.4MFY2025

From OCGN's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated OCGN in the past 90 days, not enough for a consensus
Average 12-month target
$9.50
▲ 1155.5% upside

Based on 1 analyst who set a price target on OCGN in the past 90 days. The average target is $9.50, with a high of $9.50 and a low of $9.50, compared with the last close of $0.76.

Low $9.50Avg $9.50High $9.50
Blue marker: last close $0.76
Highest target$9.50
Average target$9.50
Lowest target$9.50
Latest rating changes
HC Wainwright & Co.Maintained
Sep 10Buy$9.50
Canaccord GenuityMaintained
May 27Buy$11
DateFirmActionRatingPrice target
Sep 10HC Wainwright & Co.MaintainedBuy$9.50
May 27Canaccord GenuityMaintainedBuy$11
Loading…

Technical Analysis

OCGN · as of the Nov 17 close · updated after every close
Downtrend

The stock is 7% below its 20 day and 21% below its 50 day average. It is 83% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 40). The nearest support is the Pivot S1 at $0.74, and the nearest resistance the Pivot at $0.76.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 10.7%/day
Key levels
$2.7352 week high+259.2%
$1.38200 day average+81.6%
$1.14100 day average+50.0%
$0.9150 day average+19.7%
$0.8120 day average+6.6%
$0.80Swing high (Oct 28)+5.3%
$0.77Pivot R1+1.3%
$0.76Pivot+0.0%
$0.76Last close
$0.74Pivot S1−2.6%
$0.70Swing low (Oct 26)−7.9%
$0.6952 week low−9.2%
Indicators
RSI (14)40.50Middle of its rangeNeutral
MACD-0.02Below its signal lineBearish
Stochastic26.1Middle of its rangeNeutral
ADX (14)23.0Weak trend
Williams %R-81.9Oversold below −80, overbought above −20Oversold
CCI (20)-59.0Oversold below −100, overbought above 100Neutral
Rate of change+0.3%Change over 10 sessionsBullish
ATR (14)$0.08Typical daily range, 10.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for OCGN

What happened before

See how OCGN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow OCGN usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How OCGN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in OCGN in the last 90 days.

Loading…

See today’s whale options flow across the market →

OCGN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ●62 buying vs 58 selling
  • ●Held by funds +0.3 pts
  • ▼Funds holding -2
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding146148−1.4%
In funds' top 1000–
Held by funds43.1%42.8%+0.3 pts
New / increased20 / 4243 / 46−30.3%
Reduced / sold out35 / 2326 / 31+1.8%
Put/call ratio0.770.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See OCGN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether OCGN is in one of them and how their past OCGN trades turned out.

OCGN in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered OCGN in an article yet. Here's the latest on the wider market.

OCGN Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Dec 12
Who traded OCGN · since 2022
Latest 1 filing
$1K – $15KTraded Nov 8, 2022Filed Dec 12, 2022
PersonTypeAmountTradedFiledDelay
Christopher JacobsR · NYSell$1K – $15KNov 8, 2022Dec 12, 202234 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Ocugen

Ocugen is a company based in Malvern, Pennsylvania, that develops gene therapies for eye diseases. Its work centers on modifier gene therapies intended to treat inherited retinal diseases such as retinitis pigmentosa and Stargardt disease, as well as geographic atrophy, an advanced form of macular degeneration. The candidates are designed to be given as a single injection beneath the retina, with the aim of slowing vision loss in patients. The therapies are still in clinical development and are not yet approved for sale.

Headquarters
Malvern, PA